^
Association details:
| Biomarker: | KIT mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ipilimumab and Imatinib Mesylate in Advanced Cancer
Excerpt:
...For expansion cohorts, patients must have metastatic or unresectable gastrointestinal stromal tumor (GIST), melanoma, or uncategorized tumors with tumor biopsies that are positive for c-KIT mutations by polymerase chain reaction (PCR) or immunohistochemistry (IHC)....
Trial ID:
Source:
Title:
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
Excerpt:
...- C-kit mutation documented from either primary or metastatic tumor site...
Trial ID:
More C2 evidence
Source:
Title:
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Excerpt:
...- Patients must have either a true amplification of 4q12 or a detectable mutation of c-KIT...
Trial ID:
Source:
Title:
A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
Excerpt:
...- C-kit mutation documented from either primary or metastatic lymphnode site...
Trial ID:
Less C2 evidence
Source:
Title:
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification
Excerpt:
Forty-three patients with metastatic melanoma harboring c-Kit aberrations were enrolled on this phase II trial....The median progression-free survival (PFS) was 3.5 months, and the 6-month PFS rate was 36.6%. Rate of total disease control was 53.5%: 10 patients (23.3%; 95% CI, 10.2% to 36.4%) and 13 patients (30.2%; 95% CI, 16.0% to 44.4%) achieved partial response (PR) and stable disease (SD), respectively....Imatinib demonstrated significant activity in patients with metastatic melanoma harboring genetic c-Kit aberrations, with an overall response rate of 23.3%.
DOI:
10.1200/JCO.2010.33.9275
Source:
Title:
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
Excerpt:
The overall disease control rate was 50% but varied significantly by KIT mutation status (77% mutated v 18% amplified)...Imatinib can be effective when tumors harbor KIT mutations, but not if KIT is amplified.
DOI:
10.1158/1078-0432.CCR-15-3036
Trial ID:
